IL161841A0 - 2-Amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase - Google Patents
2-Amino-thiazoline derivatives and their use as inhibitors of inducible no-synthaseInfo
- Publication number
- IL161841A0 IL161841A0 IL16184102A IL16184102A IL161841A0 IL 161841 A0 IL161841 A0 IL 161841A0 IL 16184102 A IL16184102 A IL 16184102A IL 16184102 A IL16184102 A IL 16184102A IL 161841 A0 IL161841 A0 IL 161841A0
- Authority
- IL
- Israel
- Prior art keywords
- amino
- sub
- synthase
- inducible
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/18—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Immunology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0114510A FR2832152A1 (fr) | 2001-11-09 | 2001-11-09 | Utilisation de derives de 2-amino-thiazoline comme inhibiteurs de no-synthase inductible |
US35279702P | 2002-01-30 | 2002-01-30 | |
PCT/FR2002/003810 WO2003040115A1 (fr) | 2001-11-09 | 2002-11-07 | Derives de 2-amino-thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible |
Publications (1)
Publication Number | Publication Date |
---|---|
IL161841A0 true IL161841A0 (en) | 2005-11-20 |
Family
ID=26213260
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16184102A IL161841A0 (en) | 2001-11-09 | 2002-11-07 | 2-Amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase |
IL161841A IL161841A (en) | 2001-11-09 | 2004-05-06 | 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL161841A IL161841A (en) | 2001-11-09 | 2004-05-06 | 2-amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase |
Country Status (20)
Country | Link |
---|---|
US (4) | US6699867B2 (xx) |
EP (1) | EP1446393B1 (xx) |
JP (1) | JP2005526005A (xx) |
CN (1) | CN1314674C (xx) |
AT (1) | ATE319693T1 (xx) |
BR (1) | BR0206354A (xx) |
CA (2) | CA2669810A1 (xx) |
DE (1) | DE60209806T2 (xx) |
DK (1) | DK1446393T3 (xx) |
ES (1) | ES2256583T3 (xx) |
HR (1) | HRP20040400A2 (xx) |
HU (1) | HUP0402037A2 (xx) |
IL (2) | IL161841A0 (xx) |
MA (1) | MA27078A1 (xx) |
MX (1) | MXPA04003695A (xx) |
NO (1) | NO20033129L (xx) |
PL (1) | PL370324A1 (xx) |
PT (1) | PT1446393E (xx) |
RU (1) | RU2004117526A (xx) |
WO (1) | WO2003040115A1 (xx) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0402037A2 (hu) * | 2001-11-09 | 2005-01-28 | Aventis Pharma S.A. | 2-Amino-tiazolin-származékok alkalmazása indukálható NO-szintetáz inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
CA2628074C (en) * | 2005-10-25 | 2014-01-14 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivative |
KR20100017255A (ko) | 2007-04-24 | 2010-02-16 | 시오노기 앤드 컴파니, 리미티드 | 환식기로 치환된 아미노다이하이드로싸이아진 유도체 |
WO2008133273A1 (ja) | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | アルツハイマー症治療用医薬組成物 |
US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
US8703785B2 (en) | 2008-10-22 | 2014-04-22 | Shionogi & Co., Ltd. | 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity |
US8999980B2 (en) | 2009-12-11 | 2015-04-07 | Shionogi & Co., Ltd. | Oxazine derivatives |
JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
EP2634186A4 (en) | 2010-10-29 | 2014-03-26 | Shionogi & Co | naphthyridine |
EP2703399A4 (en) | 2011-04-26 | 2014-10-15 | Shionogi & Co | OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF |
AU2013286676B2 (en) | 2012-07-06 | 2016-12-15 | 3-D Matrix, Ltd. | Fill-finish process for peptide solutions |
WO2014065434A1 (en) | 2012-10-24 | 2014-05-01 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity |
US8865700B2 (en) * | 2012-12-20 | 2014-10-21 | Avon Products, Inc. | Collagen stimulators and their use in the treatment of skin |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0046953B1 (de) * | 1980-08-30 | 1989-12-06 | Hoechst Aktiengesellschaft | Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung |
IL87614A0 (en) | 1987-09-16 | 1989-01-31 | Abbott Lab | Peptidylheterocycles |
US5066662A (en) * | 1990-05-21 | 1991-11-19 | Warner-Lambert Company | Substituted oxazolidin-2-ones and 1,2,4-oxadiazolin-5-ones and derivatives thereof acting at muscarinic receptors |
SI9300616A (en) * | 1992-11-27 | 1994-06-30 | Wellcome Found | Enzyme inhibitors |
ATE177078T1 (de) * | 1993-10-21 | 1999-03-15 | Searle & Co | Amidino-derivate als no-synthetase inhibitoren |
WO1996014842A1 (en) * | 1994-11-15 | 1996-05-23 | Merck & Co., Inc. | Substituted heterocycles as inhibitors of nitric oxide synthase |
AR016751A1 (es) | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo |
US6420566B2 (en) * | 2000-06-09 | 2002-07-16 | Aventis Pharma S.A. | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof |
FR2810037B1 (fr) * | 2000-06-09 | 2004-04-23 | Aventis Pharma Sa | Utilisation de derives de 2-aminothiazoline comme inhibiteurs de no-synthase inductible |
US6451821B1 (en) * | 2000-06-09 | 2002-09-17 | Aventis Pharma S.A. | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase |
ATE308541T1 (de) * | 2001-11-09 | 2005-11-15 | Aventis Pharma Sa | 2-amino-4-heteroarylethyl-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase |
HUP0402037A2 (hu) * | 2001-11-09 | 2005-01-28 | Aventis Pharma S.A. | 2-Amino-tiazolin-származékok alkalmazása indukálható NO-szintetáz inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
US7361681B2 (en) * | 2003-03-28 | 2008-04-22 | Sygnis Bioscience Gmbh & Co. Kg | Method of treating amytrophic lateral sclerosis using melatonin |
-
2002
- 2002-11-07 HU HU0402037A patent/HUP0402037A2/hu unknown
- 2002-11-07 AT AT02796839T patent/ATE319693T1/de not_active IP Right Cessation
- 2002-11-07 PT PT02796839T patent/PT1446393E/pt unknown
- 2002-11-07 WO PCT/FR2002/003810 patent/WO2003040115A1/fr active IP Right Grant
- 2002-11-07 CA CA002669810A patent/CA2669810A1/fr not_active Abandoned
- 2002-11-07 RU RU2004117526/04A patent/RU2004117526A/ru not_active Application Discontinuation
- 2002-11-07 EP EP02796839A patent/EP1446393B1/fr not_active Expired - Lifetime
- 2002-11-07 JP JP2003542161A patent/JP2005526005A/ja active Pending
- 2002-11-07 PL PL02370324A patent/PL370324A1/xx unknown
- 2002-11-07 DE DE60209806T patent/DE60209806T2/de not_active Expired - Fee Related
- 2002-11-07 DK DK02796839T patent/DK1446393T3/da active
- 2002-11-07 ES ES02796839T patent/ES2256583T3/es not_active Expired - Lifetime
- 2002-11-07 MX MXPA04003695A patent/MXPA04003695A/es active IP Right Grant
- 2002-11-07 IL IL16184102A patent/IL161841A0/xx active IP Right Grant
- 2002-11-07 CA CA002465695A patent/CA2465695A1/fr not_active Abandoned
- 2002-11-07 CN CNB028245148A patent/CN1314674C/zh not_active Expired - Fee Related
- 2002-11-07 BR BR0206354-9A patent/BR0206354A/pt not_active IP Right Cessation
- 2002-11-08 US US10/291,084 patent/US6699867B2/en not_active Expired - Fee Related
-
2003
- 2003-07-08 NO NO20033129A patent/NO20033129L/no unknown
-
2004
- 2004-01-26 US US10/764,853 patent/US6953796B2/en not_active Expired - Fee Related
- 2004-04-22 MA MA27646A patent/MA27078A1/fr unknown
- 2004-05-06 IL IL161841A patent/IL161841A/en not_active IP Right Cessation
- 2004-05-06 HR HR20040400A patent/HRP20040400A2/hr not_active Application Discontinuation
-
2005
- 2005-08-10 US US11/200,713 patent/US7227022B2/en not_active Expired - Fee Related
-
2007
- 2007-04-30 US US11/742,048 patent/US20070203337A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2005526005A (ja) | 2005-09-02 |
US20030166646A1 (en) | 2003-09-04 |
CN1314674C (zh) | 2007-05-09 |
US6953796B2 (en) | 2005-10-11 |
DK1446393T3 (da) | 2006-07-10 |
NO20033129D0 (no) | 2003-07-08 |
HRP20040400A2 (en) | 2004-10-31 |
PL370324A1 (en) | 2005-05-16 |
US6699867B2 (en) | 2004-03-02 |
BR0206354A (pt) | 2003-12-23 |
EP1446393A1 (fr) | 2004-08-18 |
CA2669810A1 (fr) | 2003-05-15 |
CA2465695A1 (fr) | 2003-05-15 |
MA27078A1 (fr) | 2004-12-20 |
RU2004117526A (ru) | 2005-04-10 |
MXPA04003695A (es) | 2004-07-30 |
US20050288501A1 (en) | 2005-12-29 |
US7227022B2 (en) | 2007-06-05 |
NO20033129L (no) | 2003-08-27 |
CN1610674A (zh) | 2005-04-27 |
DE60209806D1 (de) | 2006-05-04 |
ATE319693T1 (de) | 2006-03-15 |
US20070203337A1 (en) | 2007-08-30 |
ES2256583T3 (es) | 2006-07-16 |
IL161841A (en) | 2007-07-24 |
DE60209806T2 (de) | 2006-11-02 |
WO2003040115A1 (fr) | 2003-05-15 |
US20040157843A1 (en) | 2004-08-12 |
EP1446393B1 (fr) | 2006-03-08 |
PT1446393E (pt) | 2006-05-31 |
HUP0402037A2 (hu) | 2005-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2432713A1 (en) | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same | |
TW200602322A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
IL161841A0 (en) | 2-Amino-thiazoline derivatives and their use as inhibitors of inducible no-synthase | |
YU57603A (sh) | Inhibitori fosfodiesteraze 4 | |
PL341044A1 (en) | Derivatives of orthoantranilic amide as anticoagulants | |
DK1045849T3 (da) | Purinderivater, der har phosphodiesterase IV inhiberingsaktivitet | |
HUP9802859A2 (hu) | Acil-amino-szalicilsav-amid-származékok és alkalmazásuk peszticidként | |
WO2003097656A3 (en) | Novel substituted sulfamate anticonvulsant derivatives | |
TR200102957T2 (tr) | Sitalopram hazırlanması için metod. | |
ATE491704T1 (de) | 4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten | |
WO2000059285A3 (en) | NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | |
ES2137512T3 (es) | Derivados de amidina biciclicos como inhibidores de la sintetasa de oxido nitrico. | |
NO995963L (no) | Karboksamider anvendelige som 5-HTIF-agonister | |
MXPA03011682A (es) | Derivados sustituidos de n-acil -anilina, su preparacion y su uso como medicamento. | |
NO20062152L (no) | Fremstilling av 3-azabicyklo [3.1.0.]heksanderivater | |
WO2002004416A3 (en) | Lactam metalloprotease inhibitors | |
ES2191341T3 (es) | Derivados de la 2-fenoxianilina. | |
DE69901627D1 (de) | Verfahren zur Herstellug von 3-Amino-pyrrolidinderivaten | |
WO2001060822A8 (fr) | Derives d'aminoacides et leur utilisation en tant qu'inhibiteurs de la nep, l'ace et l'ece | |
EA200300010A1 (ru) | Производные 2-аминотиазолина и их применение в качестве ингибиторов no-синтазы | |
GB9316195D0 (en) | Pharmaceuticals | |
MXPA03012073A (es) | Amidoderivados heterociclicos. | |
PE9296A1 (es) | Forma polimorfica cristalina de (s,s,s)- n- (1-[ 2- carboxi- 3-(n�- mesil- lisilamino) propil]- 1-ciclopentil carbonil )tirosina (forma o) y procesos de obtencion | |
BG105247A (en) | N-substituted azabicycloheptane derivatives, production and use thereof | |
TW200510300A (en) | Amino alcohol compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed |